Can You Get Multiple Sclerosis in Your 70s?

Multiple sclerosis can begin at any age, including in your 70s, though new-onset MS that late in life is genuinely uncommon. The disease is most frequently diagnosed between the ages of 20 and 40, and roughly 5% of cases first appear after age 50.¹ Getting diagnosed even later, in your 60s or 70s, is rarer still, but it happens often enough that neurologists have studied it as a distinct clinical entity. The picture of MS in an older adult differs from the textbook version in ways that matter for diagnosis, treatment, and daily life.

How Common Is a First Diagnosis After 60

Research going back decades has recognized that MS onset after 60 is unusual.² One study tracking MS incidence in an aging population found a mean of about four new cases per year among people aged 60 and older in a defined region, confirming that late-onset MS is a small but steady trickle rather than a medical impossibility.³ Neurologists use the umbrella term “late-onset MS” (LOMS) for cases beginning after age 50. Some researchers further distinguish “very late-onset MS” (vLOMS) for diagnoses after age 60, though there is no universally agreed-upon cutoff for that label.

The numbers are small enough that many general neurologists will see only a handful of late-onset cases in a career. That rarity itself creates problems: when a 72-year-old develops weakness in one leg or tingling in the hands, MS is usually far down the list of suspects.

Why Late-Onset MS Looks Different

If you picture MS as a disease of young women who experience episodes of numbness or blurry vision followed by recovery, late-onset MS will surprise you. The clinical profile shifts in two important ways when the disease starts later in life.

First, the disease course is different. In younger adults, the vast majority start with a relapsing-remitting pattern, meaning flare-ups followed by partial or full recovery. Among people diagnosed later, the progressive form dominates. One study found that about 83% of late-onset patients had a primary progressive course, compared with just 6% of younger-onset patients.⁴ A separate series reported primary progressive MS in 62% of late-onset cases, with another 22% developing secondary progressive disease.⁵ Progressive MS means a slow, steady worsening rather than distinct attacks, which makes it harder to notice a clear starting point.

Second, motor symptoms lead the way. Younger patients often first notice visual problems or sensory changes like tingling. In late-onset MS, the most common first complaint is difficulty walking, leg weakness, or stiffness. A systematic review and meta-analysis of published studies found motor dysfunction was the most prevalent initial symptom in late-onset MS, reported in anywhere from about 35% to 100% of patients across different studies, well ahead of sensory and visual complaints.⁶ One study put the figure at 90% for late-onset patients versus 67% for younger-onset patients.⁴

This combination, a slowly progressive course led by motor symptoms, looks a lot like normal aging, arthritis, spinal stenosis, or a dozen other conditions that are far more common in a 70-year-old. That overlap is a big part of why these cases get missed.

The Biological Shift Behind the Different Pattern

The immune system does not stay the same throughout life. As people age, the balance between different arms of immune function changes. Younger MS is driven heavily by T cells and B cells invading the central nervous system, causing the inflammatory attacks that define relapsing disease. In older adults, those adaptive immune responses are less vigorous. Instead, the main contributors to damage shift toward innate immune cells such as microglia and astrocytes, which drive a slower, smoldering neurodegeneration and disability progression.⁷ This age-related change in immune function helps explain why progressive phenotypes dominate in older patients and why the relapsing-remitting pattern is so much rarer.

Why It Gets Misdiagnosed or Diagnosed Late

Diagnostic delay in MS is already common across all ages. One study found that diagnosis was delayed in more than half of patients, with about 15% of delays caused by a neurologist’s misdiagnosis.⁸ For older adults, the odds of delay are even higher for several reasons.

The biggest confounder is white matter changes on brain MRI. Healthy people in their 70s commonly have small bright spots on MRI scans caused by age-related small-vessel disease in the brain. MS also produces white matter lesions. Distinguishing one from the other requires looking for features specific to MS, such as the Dawson’s finger sign, where lesions extend in a finger-like pattern from the brain’s ventricles, or the central vein sign, where a small vein runs through the middle of a lesion. The central vein sign in particular has been reported to distinguish MS from vascular white matter disease with very high accuracy.⁹ But not every MRI protocol is optimized to detect these signs, and not every radiologist is looking for them in a 70-year-old.

Spinal cord problems add another layer of confusion. Cervical spondylosis, a common age-related narrowing of the spinal canal, can cause weakness and numbness that closely mimics progressive MS. The two conditions can also coexist, compounding each other’s effects on the nervous system. Researchers who studied patients with both conditions found that the evaluation of anyone with known MS who develops new signs of spinal cord trouble should include spinal imaging to check whether spondylosis is contributing.¹⁰ In a patient without a known MS diagnosis, the spinal changes from spondylosis may mask or explain away what is actually MS-related damage.

Cerebrospinal fluid testing can help. One biomarker studied in both early-onset and late-onset MS showed similarly high sensitivity regardless of the patient’s age at onset, meaning the test works just as well for someone diagnosed at 65 as for someone diagnosed at 30.¹¹ That finding is reassuring, because it means diagnostic tools do not lose their usefulness in older patients. The problem is not that the tests fail; it is that they are not ordered soon enough.

How Quickly Disability Progresses

One of the harder realities of late-onset MS is that disability tends to accumulate faster than in younger-onset disease. A large Swedish nationwide study found that people with late-onset MS reached key disability milestones at roughly two to three times the rate of those with adult-onset MS after adjusting for other factors.¹² A separate Korean comparative study found that the time to needing a cane for walking was shorter for late-onset patients, though when researchers controlled for age and how long someone had the disease, the gap in overall disability scores narrowed.¹³

Data from a multinational registry added further detail. People with late-onset MS had about double the risk of progressive disability accumulation compared with younger-onset patients, and those with very late-onset MS had even steeper odds, with roughly six times the risk of reaching the point of needing a walking aid.¹⁴ The same registry data showed higher rates of conversion to a secondary progressive course and a greater likelihood of progressive disability independent of relapses.

These numbers are sobering, but they reflect averages across many patients. Individual outcomes vary. Part of the faster progression likely traces back to the progressive disease course itself, which responds less to current treatments, and part is the accumulated effect of an aging nervous system having less capacity to repair damage.

Treatment Challenges in Older Adults

Almost everything known about MS medications comes from clinical trials that enrolled adults under 55. That leaves a substantial evidence gap for anyone diagnosed later. A 2025 review in Nature Reviews Neurology put it plainly: high-efficacy treatments carry increased risks with aging, their benefits can be reduced, and little evidence exists to guide treatment in older adults.¹⁵ A separate review echoed the concern, noting that the effectiveness of disease-modifying therapies appears to decrease with age and that treatment efficacy in patients over 55 has simply not been evaluated in the pivotal trials.¹⁶

This does not mean older patients go untreated. The Korean study mentioned earlier found that a higher proportion of late-onset patients were actively receiving disease-modifying therapy compared with younger-onset patients.¹³ Neurologists do prescribe these medications for older adults; they just have less trial data to rely on and must weigh the risk of infections and other side effects that climb with age.

An interesting counterpoint applies to people who have lived with MS for decades and are now aging into their 70s, rather than being newly diagnosed. For these long-standing patients, some evidence suggests that stopping disease-modifying therapy in older age can be done safely. One clinical practice study found that patients aged 70 and older who had been free of acute disease activity for at least two years had roughly a 90% probability of remaining relapse-free after stopping treatment. Younger patients who stopped, by contrast, relapsed at much higher rates.¹⁷ Randomized trials are underway to clarify the conditions under which this can be done safely.¹⁸

How Cardiovascular Health Compounds the Picture

By the time someone is in their 70s, the odds of having hypertension, diabetes, high cholesterol, or heart disease are substantial. These are not just background noise when MS is present. A study using the Framingham cardiovascular risk score found that each one-point increase in the score was associated with a 31% higher risk of relapse and a 19% higher risk of reaching the disability milestone of needing a walking aid.¹⁹ A five-year longitudinal imaging study showed that MS patients with heart disease lost brain white matter volume at a dramatically higher rate than those without, and hypertension was linked to greater brain ventricle expansion, a marker of tissue loss.²⁰

A broader review confirmed the pattern: having type 2 diabetes, hypertension, abnormal cholesterol, or peripheral vascular disease at any point during the disease course was associated with greater disability progression.²¹ For an older adult newly diagnosed with MS, this means that managing blood pressure, blood sugar, and heart health is not a separate concern from managing MS. The two interact directly, and neglecting one accelerates the other.

The Polypharmacy Problem

Older adults with MS often take medications for several conditions at once, and those drugs can interact in ways that worsen MS symptoms. One clear example involves diuretics prescribed for blood pressure: while they help cardiovascularly, they can aggravate the bladder dysfunction that MS itself causes. Experts recommend periodic medication reviews to ensure that each prescription is still needed, still helping, and not duplicating another therapy.²² For someone newly diagnosed with MS at 72 who is already on five or six medications, adding an MS drug requires careful coordination rather than just stacking another prescription on top.

Cognitive Changes and the Alzheimer’s Question

Cognitive decline in a 70-year-old is usually attributed to normal aging or early Alzheimer’s disease. When MS is present, the picture gets complicated. A study comparing cognitive profiles of older adults with MS and those with Alzheimer’s found more overlap than most clinicians expect. Among patients with milder cognitive impairment, MS patients performed noticeably better on memory tests than Alzheimer’s patients. But among those with major cognitive impairment, the differences between the two groups largely disappeared, except that MS patients still did better on rote verbal memory tasks. The study also found that older MS patients showed both subcortical and cortical cognitive deficits, challenging the old assumption that MS only causes subcortical-type problems.²³

The practical implication is that cognitive screening in an older MS patient cannot simply follow the standard Alzheimer’s playbook. Clinicians need to consider whether cognitive decline reflects MS progression, a separate neurodegenerative process, or some combination, because the treatment approach and prognosis differ for each.

Falls, Rehabilitation, and Daily Life

Falls are one of the most immediate quality-of-life threats for an older person with MS. The risk factors are both MS-specific, like impaired balance and muscle weakness, and age-related, like reduced reaction time and medication side effects. A review of fall prevention in MS noted that falls are individual and multifactorial, and the most promising interventions combine exercise with education rather than relying on exercise alone.²⁴ For someone in their 70s, this might mean physical therapy focused on balance and leg strength paired with a home safety assessment to remove tripping hazards and install grab bars.

The caregiving side of the equation is often underappreciated. A qualitative study of MS caregivers captured the exhaustion that comes from constantly switching between the role of caregiver and the demands of the rest of life. Several participants described never being able to leave the house for more than a couple of hours and the toll of having no days off.²⁵ When the person with MS is in their 70s, the caregiver is often an aging spouse dealing with their own health challenges. Planning for respite care, home aides, and community support becomes essential early, not as a last resort.

When the Diagnosis Is Not MS at All

Because MS is rare in older adults, any diagnosis made after age 60 warrants extra scrutiny. The conditions that can mimic MS in this age group are common enough that a wrong diagnosis is a real possibility. Neuromyelitis optica spectrum disorder, sarcoidosis, central nervous system vasculitis, and B12 deficiency can all produce white matter lesions and neurological symptoms in older adults. So can cerebral small-vessel disease on its own, without any autoimmune component. The MRI features described earlier, particularly the central vein sign, help distinguish genuine MS from these mimics, but they need to be actively looked for.⁹ Getting a second opinion from a neurologist who specializes in MS is reasonable any time the diagnosis is made in someone past 60, precisely because the stakes of being wrong are high in both directions: missing MS delays treatment, and treating a non-MS condition with immunosuppressive drugs carries needless risk.